NCT01951495: A Study of Trametinib and GSK2141795 Multiple Myeloma |
|
|
| Not yet recruiting | 2 | 74 | Canada | Trametinib, GSK1120212, GSK2141795 | University Health Network, Toronto, National Cancer Institute (NCI) | Multiple Myeloma, Relapsed, Refractory | 10/15 | 03/16 | | |
| Active, not recruiting | 1/2 | 27 | US | Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Dabrafenib Mesylate, Dabrafenib Methanesulfonate, GSK2118436 Methane Sulfonate Salt, GSK2118436B, Tafinlar, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Trametinib Dimethyl Sulfoxide, Mekinist, Meqsel, Spexotras, Uprosertib, GSK2141795, Oral Akt Inhibitor GSK2141795 | National Cancer Institute (NCI), GlaxoSmithKline, Novartis Pharmaceuticals | Hematopoietic and Lymphoid Cell Neoplasm, Locally Advanced Malignant Solid Neoplasm, Locally Advanced Melanoma, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Unresectable Malignant Solid Neoplasm, Unresectable Melanoma | 05/18 | 10/25 | | |
